Phase II trial of capecitabine + bevacizumab as maintenance treatment after initial treatment with XELOX in previously untreated metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: Patients receive XELOX(+BEV) for 4 cycles, they then receive XEL+BEV until PD, they finally receive XELOX(+BEV) until PD. Primary outcome(s): Duration of disease control Study Design: Single arm Non-randomized
创建时间：
2011-07-15
